ABSTRACT
Concomitant pathology is a risk factor for severe COVID-19. Bilateral changes characteristic of sarcoidosis onCTscan can also occur with coronavirus infection.The purpose of the study: based on our own data to study the features of the course of a new coronavirus infectionin patients with lung sarcoidosis.Materials and methods: 47 patients have been under observation which accounted for 22.4% of the total number ofobserved patients with sarcoidosis. Concomitant pathology: cardiovascular system - 24.9%, gastrointestinal tractpathology - 23.3%, COPD and bronchial asthma in 11.7%, diabetes mellitus in 5.25%. As a basic therapy, 74.5%received GCS, 5.2% - methotrexate, 16.2% - GCS +methotrexate. In addition, 32% took vitamin E and 19.8% -pentoxifylline.Results and discussion: The average age of patients is 37.2+/-3.4 (men 12, women 35). In 8 patients - pneumoniawas not detected;in 21 patients (CT stage 1) SpO2 95.2+/- 2.4%, in 15 patients (CT stage 2) SpO2 86.0+/- 4.5%, in 4patients (CT stage 3) COVID-19 had a severe SpO2 68.1+/- 7.3%, which required treatment in the intensive care unit. Blood parameters: IL-6 - 94.3+/-7.8 (N less than 3.4 ng/ml), CRP 103.4+/-8.9 (N 0-5 mg/L), ACE 82.3+/-7.3 (N 8-52 units/L), D-dimer 485+/-20.8 (N less than 442 ng/ml), ferritin 643.4+/-10.7 (N 28-365 ng/ml), GGT 104.5+/-3.7 (N 1-55 Units/L), procalcitonin 0.17 +/- 0.01 (N less than 0.1ng/ml). Conclusion(s): based on the data obtained, a severe course of COVID-19 was noted in 6.38% of patients with sarcoidosis, the course of moderate severity in 32%. The factors contributing to the severe course include the use of cytostatics and GCS.